Akebia Therapeutics, Inc. (AKBA)
0.9803
+0.04
(+3.77%)
USD |
NASDAQ |
Sep 02, 16:00
0.983
0.00 (0.00%)
Pre-Market: 20:00
Akebia Therapeutics Research and Development Expense (TTM) : 68.91M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 68.91M |
| March 31, 2026 | 66.13M |
| December 31, 2025 | 61.09M |
| September 30, 2025 | 42.02M |
| June 30, 2025 | 35.52M |
| March 31, 2025 | 32.07M |
| December 31, 2024 | 31.99M |
| September 30, 2024 | 34.21M |
| June 30, 2024 | 39.02M |
| March 31, 2024 | 51.57M |
| December 31, 2023 | 61.49M |
| September 30, 2023 | 84.39M |
| June 30, 2023 | 99.07M |
| March 31, 2023 | 104.88M |
| December 31, 2022 | 129.01M |
| September 30, 2022 | 125.76M |
| June 30, 2022 | 138.14M |
| March 31, 2022 | 149.24M |
| December 31, 2021 | 145.92M |
| September 30, 2021 | 153.87M |
| June 30, 2021 | 160.22M |
| March 31, 2021 | 175.80M |
| December 31, 2020 | 216.41M |
| September 30, 2020 | 259.76M |
| June 30, 2020 | 287.93M |
| Date | Value |
|---|---|
| March 31, 2020 | 321.32M |
| December 31, 2019 | 322.97M |
| September 30, 2019 | 329.67M |
| June 30, 2019 | 325.79M |
| March 31, 2019 | 312.02M |
| December 31, 2018 | 291.07M |
| September 30, 2018 | 272.34M |
| June 30, 2018 | 260.41M |
| March 31, 2018 | 232.25M |
| December 31, 2017 | 230.89M |
| September 30, 2017 | 195.95M |
| June 30, 2017 | 168.47M |
| March 31, 2017 | 155.60M |
| December 31, 2016 | 115.58M |
| September 30, 2016 | 94.63M |
| June 30, 2016 | 79.11M |
| March 31, 2016 | 55.32M |
| December 31, 2015 | 42.72M |
| September 30, 2015 | 37.28M |
| June 30, 2015 | 28.20M |
| March 31, 2015 | 26.63M |
| December 31, 2014 | 25.36M |
| September 30, 2014 | 21.50M |
| June 30, 2014 | 18.10M |
| March 31, 2014 | 15.04M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Emergent BioSolutions, Inc. | 45.30M |
| Exelixis, Inc. | 824.32M |
| ADMA Biologics, Inc. | 11.52M |
| Arcutis Biotherapeutics, Inc. | 91.04M |
| Relay Therapeutics, Inc. | 270.72M |